608 related articles for article (PubMed ID: 29229282)
1. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
2. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
[TBL] [Abstract][Full Text] [Related]
3. Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit.
Sebire NJ; Foskett M; Short D; Savage P; Stewart W; Thomson M; Seckl MJ
BJOG; 2007 Jun; 114(6):760-2. PubMed ID: 17516969
[TBL] [Abstract][Full Text] [Related]
4. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
5. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
6. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
7. A Case of Rapid Transformation from Hydatidiform Mole to Invasive Mole: The Importance of β-hCG (Human Chorionic Gonadotropin) Serum Levels in Follow-Up Evaluation.
Harsono AB; Hidayat YM; Winarno GNA; Nisa AS; Alkaff FF
Am J Case Rep; 2021 Jun; 22():e931156. PubMed ID: 34127641
[TBL] [Abstract][Full Text] [Related]
8. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
9. Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis.
Albright BB; Shorter JM; Mastroyannis SA; Ko EM; Schreiber CA; Sonalkar S
Obstet Gynecol; 2020 Jan; 135(1):12-23. PubMed ID: 31809433
[TBL] [Abstract][Full Text] [Related]
10. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
11. Histopathological diagnosis of hydatidiform mole: contemporary features and clinical implications.
Sebire NJ
Fetal Pediatr Pathol; 2010; 29(1):1-16. PubMed ID: 20055560
[TBL] [Abstract][Full Text] [Related]
12. Late spontaneous resolution of persistent molar pregnancy.
Taylor F; Short D; Harvey R; Winter MC; Tidy J; Hancock BW; Savage PM; Sarwar N; Seckl MJ; Coleman RE
BJOG; 2016 Jun; 123(7):1175-81. PubMed ID: 26774079
[TBL] [Abstract][Full Text] [Related]
13. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
[TBL] [Abstract][Full Text] [Related]
14. Guidelines following hydatidiform mole: a reappraisal.
Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and outcome of hydatidiform moles in missed-miscarriage: a cohort-study, systematic review and meta-analysis.
Memtsa M; Johns J; Jurkovic D; Ross JA; Sebire NJ; Jauniaux E
Eur J Obstet Gynecol Reprod Biol; 2020 Oct; 253():206-212. PubMed ID: 32877774
[TBL] [Abstract][Full Text] [Related]
16. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
18. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
19. Rapid progression from complete molar pregnancy to post-molar gestational trophoblastic neoplasia: a rare case report and literature review.
Qian J; Gracious K; Sun L
Front Oncol; 2023; 13():1303249. PubMed ID: 38162509
[TBL] [Abstract][Full Text] [Related]
20. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France.
Descargues P; Hajri T; Massardier J; Lotz JP; Devouassoux-Shisheboran M; Allias Montmayeur F; You B; Golfier F; Bolze PA
Am J Obstet Gynecol; 2021 Oct; 225(4):401.e1-401.e9. PubMed ID: 34019886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
